Cures & Capital

In this episode, we speak with Jan Lundberg – former President of Lilly Research Laboratories and Head of R&D at Eli Lilly and Company.With a career spanning academia, biotech, and big pharma, Jan has contributed to the development of more than 30 approved medicines, including Brilinta, Iressa, Nexium, Taltz, Trulicity, Verzenio, and Tirzepatide (Mounjaro). He also played a central role in one of the most remarkable growth stories in the industry.We explore what it really takes to turn around an R&D organization – from inheriting late-stage failures and pipeline setbacks to rebuilding decision-making, culture, and scientific rigor. We dive into the core levers behind this transformation, with a particular focus on culture – from empowering teams and simplifying decision-making to fostering true cross-functional collaboration across the value chain.We also discuss decision-making under uncertainty in pharma – how experienced leaders balance data with judgment, and what it really means to make high-stakes portfolio decisions. Along the way, Jan shares candid insights on competition with Novo Nordisk, the evolution of the GLP-1 space, and why long-term success ultimately comes down to people, culture, and scientific courage.If you want to connect with us:LinkedIn: https://www.linkedin.com/company/cures-capital-podcastYou can find this podcast on YouTube, Spotify or Apple Podcasts - just search for Cures & Capital.If you want to connect with Jan Lundberg:LinkedIn: https://www.linkedin.com/in/jan-m-lundberg-77729a95/Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

How do investors really value biotech? Former hedge fund investor and biotech analyst Hartaj Singh explains how Wall Street thinks about risk, biology, clinical trials, and uncertainty - and why biotech valuation is both art and formula.Hartaj Singh on LinkedIn:https://www.linkedin.com/in/hartaj-s-35614670/Check out Hartaj's newsletter:The Biotech Capital Compass - https://hartajsingh1.substack.com/Subscribe to the Cures & Capital podcast on YouTube, Apple Podcasts, and Spotify!Make sure to follow us on LinkedIn:linkedin.com/company/cures-capital-podcastDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic implications behind them, and explore what it really takes to bring these breakthroughs to market.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode in video format, you can also get the podcast on YouTube, just search for Cures & Capital.If you want to connect with Jeff Holder:Linkedin: https://www.linkedin.com/in/jeff-holder-ph-d-7a391087/If you want to connect with Adam Siebert:Linkedin: https://www.linkedin.com/in/adam-siebert-8772b327/If you want to read more about/from L.E.K. Consulting:Website: https://www.lek.com/Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode of Cures & Capital, Dr. Sheila Gujrathi — biotech entrepreneur, investor, and former CEO of Gossamer Bio — shares her perspective on how to elevate female leaders and underrepresented voices in biopharma.She discusses lessons from her 25+ years leading companies and investments, and why inclusive leadership is key to innovation and value creation.We also dive into her book, The Mirror Effect, and her mission to inspire the next generation of women in biotech.Check out Sheila's book (released Nov. 4, 2025) on her website:https://sheilagujrathimd.com/book/ 🎙️ Hosted by Martin Slezak and Simon Birksø Cures & Capital — the podcast about value creation in biotech and pharma.We are also on YouTube ---> SUBSCRIBE and be part of the conversation!Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development.We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adaptive and Bayesian designs that evolve with the data. Scott breaks down why these methods can de-risk programs, optimize capital use, and accelerate decision-making, while still maintaining scientific and regulatory rigor.We also discuss adoption barriers, cultural inertia in big pharma and the evolving stance of regulators. Along the way, Scott shares insights on trial efficiency, Bayesian thinking in investment committees, and why he expects future of drug development to look much more Bayesian than it is today.If you want to connect with us:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to get the episodes in an audio form, you can get the podcast from Spotify and Apple Podcasts, just search for Cures & Capital.If you want to connect with Scott or follow up on some of his work:Linkedin: https://www.linkedin.com/in/scott-berry-52b8025b/Berry Consultants: https://www.berryconsultants.com/In the Interim: https: https://www.berryconsultants.com/podcastDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Deborah Dunsire, board chair at Neurvati Neurosciences, multiple times board member, and a former CEO of Lundbeck. With more than 3 decades of experience, Deborah has navigated organizations of every size through change, uncertainty, and opportunity.We explore what it takes to lead in today’s biopharma landscape - from rolling up your sleeves in biotech to streamlining decisions in big pharma, and from balancing short-term survival in a capital-constrained environment to laying the groundwork for long-term innovation. Deborah also shares insights on the interplay between boards and executive teams, the pitfalls of wishful thinking in drug development, and why engaging beyond the four walls of a company is essential for shaping the future of the industry.Chapters:00:00 - Intro01:08 - Guest introduction: Deborah Dunsire01:51 - Growth experiences03:40 - Lessons big pharma and biotech can learn from each other12:51 - Behind the strategy table - strategic leadership in biopharma23:22 - Navigating the biotech “winter” - prioritization & survival strategies32:22 - Beyond the company - ecosystem engagement and policy influence43:27 - Diversity, leadership and women in pharma53:54 - Final reflections and book recommendations56:07 - Reflections and takeawaysIf you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode in video format, you can also get the podcast on YouTube, just search for Cures & Capital.If you want to connect with Deborah Dunsire:Linkedin: https://www.linkedin.com/in/deborahdunsire/Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Dr. Andrée Bates, founder and CEO of Eularis, a company helping clients accelerate pharma business results through Artificial Intelligence.We explore how the biopharma industry can move beyond scattered pilots toward strategic, enterprise-wide AI integration. Drawing on decades at the forefront of AI in pharma, Dr. Bates shares practical insights on building the foundations for long-term value creation and turning AI into a true competitive advantage. We also dig into how to calculate ROI on AI, avoid the “spray and pray” trap, and why the future of pharma might look more like science fiction than we think.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcast You can also watch this episode on YouTube, just search for Cures & Capital. If you want to connect withDr. Andrée Bates:Linkedin: https://www.linkedin.com/in/dr-andree-bates/ Or get in touch with Eularis:Linkedin: https://www.linkedin.com/company/eularis/Website: https://eularis.com If you would like to read Romy & Roby:Website: https://romyandroby.aiDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

How did China become a serious force in global biotech in just over a decade?This is the insider story of China's biotech boom!Dr. Leon 'Jun' Tang, founding partner of InScienceWeTrust BioAdvisory, joins Cures & Capital to unpack the rise of Chinese biopharma.From talent migration and government planning to innovation in ADCs and the challenges of commercialization.Chapters00:00 - Introduction & Leon’s global background01:13 - Guest introduction - Leon 'Jun' Tang05:35 - Impact of Chinese biotech innovation at biomedical conferences14:30 - The wave of China-to-West licensing deals18:00 - Understanding the rise of China's biotech industry22:00 - Push & pull: why Chinese scientists leave the West24:40 - Government strategy & capital markets as biotech catalysts34:30 - Could India, Africa, or the Middle East replicate China’s path?37:25 - How do Chinese biotech industry parks look in practice?46:46 - How fast and cost-effective are Chinese biotech companies?52:05 - Impact of Chinese biotech on the US and EU59:26 - When will China have its own Pfizer or Eli Lilly?01:05:30 - Closing reflections by Martin & SimonIf you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to get the episodes as just audio, you can also get the podcast from Spotify and Apple Podcasts.If you want to connect with Leon:https://www.linkedin.com/in/leontangbiotech/Here's a link to Leon's article in Nature Reviews Drug Discovery:Analysis of China-to-West pharmaceutical licensing deals in 2024Nature Reviews Drug Discovery 24, 411-412 (2025)doi: https://doi.org/10.1038/d41573-025-00068-0Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches.This conversation is a practical guide to new drug launches, packed with Jason's hard-won insights. We explore why so many launches fail, the psychology behind adoption resistance, what meaningful relative advantage really means, how to plan for a successful launch, and when you actually need to start thinking about commercialization.This episode will shift how you think about launching new drugs, and what it truly takes to do it successfully.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode as a video, you can also get the podcast from YouTube, just search for "Cures & Capital".If you want to connect with Jason:Linkedin: https://www.linkedin.com/in/jason-o-neill-1b8a2349/You can get his new book "The secrets of successful drug launches" from:Amazon: https://www.amazon.com/Secrets-Successful-Drug-Launches/dp/B0DZ6RFTCNThis book is packed with insights and practical tips, and all proceeds go to the Prostate Cancer Foundation in memory of Jason’s father. Buying it is truly a win-win, you gain valuable knowledge while supporting a meaningful cause. Links to some of the articles and books that we discussed in this episode:McKinsey's analysis on "Pharma’s first-to-market advantage" Link: https://www.mckinsey.com/industries/life-sciences/our-insights/pharmas-first-to-market-advantage#/Paper: "Pharmaceutical forecasting: throwing darts?"Link: https://www.nature.com/articles/nrd4127HBR articles:"Eager Sellers and Stony Buyers: Understanding the Psychology of New-Product Adoption"Link: https://hbr.org/2006/06/eager-sellers-and-stony-buyers-understanding-the-psychology-of-new-product-adoption"Marketing Malpractice: The Cause and the Cure"Link: https://hbr.org/2005/12/marketing-malpractice-the-cause-and-the-cure"What is Strategy?"Link: https://hbr.org/1996/11/what-is-strategy"The Hidden Traps in Decision Making"Link: https://hbr.org/1998/09/the-hidden-traps-in-decision-making-2Books:"Diffusion of Innovation"Link: https://www.goodreads.com/book/show/75599989-diffusion-of-innovations-5th-edition?from_search=true&from_srp=true&qid=HrX5m6p9k8&rank=2"Poor Charlie's Almanack: The Wit and Wisdom of Charles T. Munger"Link: https://www.goodreads.com/book/show/944652.Poor_Charlie_s_AlmanackDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Jason O’Neill, former CEO of Dendreon and Iridium Therapeutics, and author of The Secrets of Successful Drug Launches.This conversation is a practical guide to new drug launches, packed with Jason's hard-won insights. We explore why so many launches fail, the psychology behind adoption resistance, what meaningful relative advantage really means, how to plan for a successful launch, and when you actually need to start thinking about commercialization.This episode will shift how you think about launching new drugs, and what it truly takes to do it successfully.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode as a video, you can also get the podcast from YouTube, just search for "Cures & Capital".If you want to connect with Jason:Linkedin: https://www.linkedin.com/in/jason-o-neill-1b8a2349/You can get his new book "The secrets of successful drug launches" from:Amazon: https://www.amazon.com/Secrets-Successful-Drug-Launches/dp/B0DZ6RFTCNThis book is packed with insights and practical tips, and all proceeds go to the Prostate Cancer Foundation in memory of Jason’s father. Buying it is truly a win-win, you gain valuable knowledge while supporting a meaningful cause. Links to some of the articles and books that we discussed in this episode:McKinsey's analysis on "Pharma’s first-to-market advantage" Link: https://www.mckinsey.com/industries/life-sciences/our-insights/pharmas-first-to-market-advantage#/Paper: "Pharmaceutical forecasting: throwing darts?"Link: https://www.nature.com/articles/nrd4127HBR articles:"Eager Sellers and Stony Buyers: Understanding the Psychology of New-Product Adoption"Link: https://hbr.org/2006/06/eager-sellers-and-stony-buyers-understanding-the-psychology-of-new-product-adoption"Marketing Malpractice: The Cause and the Cure"Link: https://hbr.org/2005/12/marketing-malpractice-the-cause-and-the-cure"What is Strategy?"Link: https://hbr.org/1996/11/what-is-strategy"The Hidden Traps in Decision Making"Link: https://hbr.org/1998/09/the-hidden-traps-in-decision-making-2Books:"Diffusion of Innovation"Link: https://www.goodreads.com/book/show/75599989-diffusion-of-innovations-5th-edition?from_search=true&from_srp=true&qid=HrX5m6p9k8&rank=2"Poor Charlie's Almanack: The Wit and Wisdom of Charles T. Munger"Link: https://www.goodreads.com/book/show/944652.Poor_Charlie_s_AlmanackDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

Over the past few months, we’ve had the chance to speak with some of the sharpest minds in the industry—thinkers and practitioners who have shaped how we understand drug innovation, R&D productivity, portfolio strategy, and other critical topics.In this episode, we bring together the major insights and lessons, highlighting patterns that emerged across the different conversations.We also spotlight the unique takeaways from each guest to help ensure these key learnings really stick. Whether you're an R&D leader, investor, innovator, or strategist, these insights will help you rethink how to create real, lasting value in an industry undergoing rapid change.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to get the episodes as just audio, you can also get the podcast from Spotify and Apple Podcasts.Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we talk to Aaron Schact, the CEO and Board Director at BiomEdit and former R&D leader at Eli Lilly and Elanco. We discuss how to improve biopharma's R&D productivity and the industry's "grand challenge", why R&D productivity is the mental model for managing R&D at scale, practical advice on how to approach and work with R&D productivity, and much more!If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode as a video, you can also get the podcast from YouTube, just search for "Cures & Capital".If you want to connect with Aaron or read about BiomEdit:Linkedin: https://www.linkedin.com/in/aaronlschacht/BiomEdit: https://www.biomedit.comResearch paper: "How to improve R&D productivity: the pharmaceutical industry's grand challenge"Link: https://www.nature.com/articles/nrd3078Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, our guest is Dr. Matthias Krings - a senior partner at Catenion, a biopharma strategy consulting firm.Matthias is a seasoned veteran in biopharma strategy.In this conversation, he shares his playbook for achieving success as a biopharma company.As critical pillars for biopharma success, we dive into strategy processes, decision-making, and effective R&D risk management.If you want to connect with us - we would love to hear from you:LinkedIn: https://www.linkedin.com/company/cures-capital-podcastYou can also watch the full episode on our YouTube channel.Get in touch with Catenion: www.catenion.comYou can get in touch with Matthias through the Catenion website or via LinkedIn. Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

How do venture capitalists think? And how do they define and create value in the life science industry?In this episode, we talk to Stephan Christgau, founding partner of Eir Ventures, about the VC mindset, investment decision-making and portfolio strategy. We dive into how VCs assess risk, balance high-stakes opportunities, and what could pharma and biotech companies learn from the VC way of doing things.If you want to connect with us - we would love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to get the episodes as a video, you can watch our talking heads on YouTube.If you want to connect with Stephan or read about Eir Ventures:Linkedin: https://www.linkedin.com/in/stephan-christgau-6464392/Eir Ventures: https://www.linkedin.com/company/eir-ventures/Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, we sit down with Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, to discuss the trends shaping the life sciences industry in 2025 and beyond.How do we navigate the life sciences industry in times of great uncertainty?Murray has observed the life sciences industry for decades and lays out his balanced perspective of the state of the industry and the underlying uncertainties, challenges and opportunities. This episode is a must-watch for anyone who wants to know what is going on in the industry. If you want to connect with us - we'd love to hear from you:Linkedin: https://www.linkedin.com/company/cures-capital-podcastIf you prefer to watch the episode, check our YouTube channel:https://www.youtube.com/@CuresCapitalIf you want to connect with Murray or follow up on the latest insights from IQVIA:Linkedin: https://www.linkedin.com/in/murray-aitken-iqviainstitute/IQVIA: https://www.iqvia.com/Report: 2025 Indicators of Progress for Advancing Health GloballyLink: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/2025-indicators-of-progress-for-advancing-health-globallyReport: Global Trends in R&D 2024: Activity, productivity, and enablersLink: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablersDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, Mike Rea - CEO, IDEA Pharma - takes us on a journey through innovation and value creation in pharma. It is not all roses!He shares his candid views on what the pharmaceutical industry needs to do better to be less confused about innovation.Mike Rea also explains the importance of getting the definition of innovation right in drug development. Early commercial involvement in drug R&D is another key pillar in his drug innovation philosophy.We also get to discuss organizational design and team size conducive to unlocking pharma's innovation potential.You can easily get in touch with Mike Rea through LinkedIn, X, etc.If you want to connect with us - and join the discussions with other listeners:Linkedin: https://www.linkedin.com/company/cures-capital-podcastYouTube - watch the interview:https://www.youtube.com/@CuresCapitalDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innovation and more. Kelvin Stott has over 20 years of diverse leadership experience in pharma R&D strategy and operations, drug discovery and development, portfolio management, strategy consulting, biotech start-ups and venture capital. Currently, he is the Founder and CEO of Amporin Pharmaceuticals.If you want to connect with us:Linkedin: https://www.linkedin.com/company/cures-capital-podcastYouTube - watch the interview:https://www.youtube.com/@CuresCapitalIf you want to connect with Kelvin or follow up on some of his work:Linkedin: https://www.linkedin.com/in/kelvinstott/Amporin Pharmaceuticals: https://www.linkedin.com/company/amporin/Article: Pharma's broken business model - Part 1: An industry on the brink of terminal declineLink: https://www.linkedin.com/pulse/pharmas-broken-business-model-industry-brink-terminal-kelvin-stott/Article: Pharma's broken business model - Part 2: Scraping the barrel in drug discoveryLink: https://www.linkedin.com/pulse/pharmas-broken-business-model-part-2-scraping-barrel-kelvin-stott/Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more.If you're looking to deepen your understanding of these areas, there's no better guide than Jack.Jack brings a deep and holistic understanding of the biotech and pharma industry, having held a variety of roles—including being a neuroscientist, strategy consultant, investment analyst, and now the CEO of Etheros Pharmaceuticals.Chapters:00:00 Intro02:08 Guest introduction - Dr. Jack Scannell05:46 R&D productivity from past to present to future34:00 Decision making, model validity and quality56:00 Practitioner's view and advice01:04:04 Closing remarks with Jack01:05:45 Episode summary and discussion with Martin and SimonIf you want to connect with us:Linkedin: https://www.linkedin.com/company/cures-capital-podcastYouTube - watch the interview:https://www.youtube.com/@CuresCapitalIf you want to connect with Jack or follow up on some of his work:Linkedin: https://www.linkedin.com/in/jack-scannell-554b28/X: https://x.com/jackscannell13Etheros Pharmaceuticals: https://etherospharma.comPaper: Diagnosing the decline in pharmaceutical R&D efficiency Link: https://www.nature.com/articles/nrd3681Paper: Predictive validity in drug discovery: what it is, why it matters and how to improve it Link: https://www.nature.com/articles/s41573-022-00552-xPaper: When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis Link: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147215Paper: Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (Novel approach to DCF valuation of biopharma assets is here in Supplementary Data 2 of the paper) Link: https://www.nature.com/articles/s43856-022-00209-1Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

EPISODE 1 - Cures & Capital: Trailer EpisodeIn this episode, we introduce the scope and mission of the podcast.Our focus with Cures & Capital is the intersection between drug R&D and finance. Hosts: Martin Slezak & Simon Birksø.Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.